Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage.
about
Enhanced transdermal delivery of salbutamol sulfate via ethosomes.Ultradeformable liposomes with terpenes for delivery of hydrophilic compound.Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle arrayEffect of surfactant mixtures on skin structure and barrier properties.Nanotransfersomes of carvedilol for intranasal delivery: formulation, characterization and in vivo evaluation.Nanocarriers to Enhance the Accumulation of Vitamin K1 into the Skin.Propylene glycol liposomes as a topical delivery system for miconazole nitrate: comparison with conventional liposomesImproved skin permeation of methotrexate via nanosized ultradeformable liposomes.Liposomes in the treatment of inflammatory disorders.Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations.Cutaneous short-interfering RNA therapy.Charged liposomes as carriers to enhance the permeation through the skin.Liposomal systems as drug delivery vehicles for dermal and transdermal applications.Bioactive glasses as carriers for bioactive molecules and therapeutic drugs: a review.Advanced systems for glucocorticoids' dermal delivery.Comprehensive review on additives of topical dosage forms for drug delivery.Nanomedicine strategies for targeting skin inflammation.Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.Review and the state of the art: Sol-gel and melt quenched bioactive glasses for tissue engineering.Needle-free jet injection of intact phospholipid vesicles across the skin: a feasibility study.Systematic prediction of drug combinations based on clinical side-effects.Phosphatidyl choline-based colloidal systems for dermal and transdermal drug delivery.Transdermal delivery of butamben using elastic and conventional liposomes.Adaptability and elasticity of the mixed lipid bilayer vesicles containing non-ionic surfactant designed for targeted drug delivery across the skin.Stability evaluation of temoporfin-loaded liposomal gels for topical application.Transfersomal lyophilized gel of buspirone HCl: formulation, evaluation and statistical optimization.Localized delivery of cisplatin for the effective management of squamous cell carcinoma from protransfersome formulation.Skin permeation of retinol in Tween 20-based deformable liposomes: in-vitro evaluation in human skin and keratinocyte models.Effect of Different Skin Penetration Promoters in Halobetasol Propionate Permeation and Retention in Human Skin.Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen.Getting Drugs Across Biological Barriers.Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases.Liposomal hydrogel formulation for transdermal delivery of pirfenidone.Hydrogels and Their Combination with Liposomes, Niosomes, or Transfersomes for Dermal and Transdermal Drug DeliveryA β-cyclodextrin, polyethyleneimine and silk fibroin hydrogel containing Centella asiatica extract and hydrocortisone acetate: releasing properties and in vivo efficacy for healing of pressure soresInfluence of the flexible liposomes on the skin deposition of a hydrophilic model drug, carboxyfluorescein: dependency on their composition
P2860
Q33313608-F5FE6EF3-E1B9-44F7-A603-196B72F8E03FQ34291684-9BAFFF48-957F-48C6-B10C-E817694D05B4Q34414393-B300DCA6-348B-4C34-B2BE-CD8DBD71207DQ34751237-816DD72A-5852-4F28-89A5-1E89CC30C5E3Q35567800-C1433B81-02BB-421E-8DD9-5A3CF41B80C8Q35856187-AB529505-35AB-46FF-B1B4-18D45F1A37BDQ35999109-2B2AA220-C6B1-4990-9379-EC77EE48F717Q36107740-FC67B64B-0D41-47A0-976C-4A208720F352Q36316769-2F26DFEB-89D1-4A90-9091-30BBCDE0A62BQ37125441-77FB6CA6-8345-4721-9B50-44DC66D9A5FAQ37639312-3797CC05-7065-440B-8734-34A610100DE1Q37873946-034D248B-8FA4-4FEE-A048-32CCE56C2725Q37909120-79F1B36E-ADF6-4136-B49D-A5475F987439Q37987823-7C27571F-0CFE-4991-AD7B-45C2CC021CC8Q38094761-8216E10B-220B-48C4-8F9C-AC1974177A05Q38181173-6D561EC0-715A-4E35-9BBA-1FCAADA41A75Q38260735-87F29D3E-84C1-4DCB-8ACD-602EBD2C891AQ38273695-82D90A4C-960D-4F6E-8D7E-98D479D4B066Q38523506-439C8215-7246-47B0-94ED-AE0F449F4685Q39597224-9DFEAC1B-10B6-45B9-B6F0-ED73E7FCA0E3Q42050971-F4A4B52B-0F23-4C84-AFEB-2BFC7CB565F9Q43253529-477E55B0-A100-453D-B842-2B32291F3088Q44396472-B5CF3BD0-3F58-4C74-B34C-AA8115D2BD4BQ45231396-AFE4608F-293D-4239-973F-0F194F9B7CF5Q45951077-F3B879E4-F425-40A0-A2B7-E6C8F24CF40DQ46506603-AFEBD5A9-1D96-4074-9E1D-17F90E1C5A5DQ46766567-2C7F1D93-02D3-42DE-AE1C-01B5F5E1CE4AQ46922935-BDF8B826-7C24-4D06-A5B5-55854F5ED92EQ47168310-69A8138C-ADB6-4029-AF62-2D1C26BDEB0FQ47375550-8D167024-30F1-4ECD-BACD-F888D01992BAQ48331228-F9D13E21-CB33-4BA8-8A5A-8F3F92F95174Q50268454-200EDB30-718A-4E0C-810E-9BBEB15CBDF4Q53452813-4C533C4E-8631-4D1E-8A3C-2A9F429F5A12Q56035470-8971CFA6-70BA-477E-B6FC-A0066E443D8BQ57217897-5ED4480C-D030-4DB2-9F63-D859F97D39F9Q58914571-EAFE2530-63AA-4759-842E-CB24236D15B3
P2860
Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Hydrocortisone and dexamethaso ...... nd reduced therapeutic dosage.
@en
Hydrocortisone and dexamethaso ...... nd reduced therapeutic dosage.
@nl
type
label
Hydrocortisone and dexamethaso ...... nd reduced therapeutic dosage.
@en
Hydrocortisone and dexamethaso ...... nd reduced therapeutic dosage.
@nl
prefLabel
Hydrocortisone and dexamethaso ...... nd reduced therapeutic dosage.
@en
Hydrocortisone and dexamethaso ...... nd reduced therapeutic dosage.
@nl
P1476
Hydrocortisone and dexamethaso ...... nd reduced therapeutic dosage.
@en
P2093
Gabriele Blume
Gregor Cevc
P356
10.1016/J.BBAMEM.2004.01.006
P577
2004-05-01T00:00:00Z